Close Menu

NEW YORK – Women's health diagnostic firm Progenity has hit bumps in the road in the eight years since it began, including multiple issues with the federal regulators and private insurers.

Meanwhile, its CEO tenure while he was at noninvasive prenatal testing firm Sequenom was also marred by a scandal.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.